Welcome to the new morningstar.co.uk! Learn more about the changes and how our new features help your investing success.

AstraZeneca Gets US FDA Thumps Up For Glycaemia Control Treatment

LONDON (Alliance News) - Drugmaker AstraZeneca PLC has received US regulatory approval for a ...

Alliance News 3 May, 2019 | 8:01AM
Email Form

LONDON (Alliance News) - Drugmaker AstraZeneca PLC has received US regulatory approval for a proposed treatment for adults with type-2 diabetes, it said Friday.

Qternmet XR, which is a combination of dapagliflozin, saxagliptin, and metformin hydrochloride, is an oral, once-a-day treatment to improve glycaemic control in adults with the condition.

The approval from the US Food & Drug Administration comes after two phase III trials, which both showed positive results.

By George Collard; georgecollard@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 7,275.00 GBX 0.37

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites